FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1504-1507 April 3, 2008 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kastelein, J. J.P. PubMed Citation

In this issue of the Journal, Kastelein et al.¹ report the results of a 2-year study comparing daily therapy with 80 mg of simvastatin plus either placebo or 10 mg of ezetimibe on the average change in carotid intima–media thickness in patients with familial hypercholesterolemia. The study, called the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial, showed no significant between-group differences in any of several end points with respect to intima–media thickness (a commonly used risk surrogate for vascular disease) or clinical results, despite a between-group difference in levels of low-density lipoprotein (LDL) cholesterol of 51 mg . . . [Full Text of this Article]

Source Information

From the University of Washington School of Medicine, Seattle (B.G.B.); and the Uniformed Services University of the Health Sciences, Bethesda, MD, and the Cardiology Service, Walter Reed Army Medical Center, Washington, DC (A.J.T.).

This article (10.1056/NEJMe0801608) was published at www.nejm.org on March 30, 2008.

Related Letters:

Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Steinberg D., Eichhorn E. J., Connor W. E., Diamond G. A., Kaul S., Blake J. A., Davis H. R. Jr., Murgolo N. J., Graziano M. P., Kaye T., Akdim F., de Groot E., Kastelein J. J.P., Brown B. G.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:529-533, Jul 31, 2008. Correspondence

This article has been cited by other articles:

• Stein, E. A. (2008). Additional Lipid Lowering Trials Using Surrogate Measurements of Atherosclerosis by Carotid Intima-Media Thickness: More Clarity or Confusion?. J Am Coll Cardiol 0: j.jacc.2008.11.002v1-14350 [Full Text]  
• Stebbing, J., Asghar, A. K., Holmes, P., Bower, M., Isenman, H. L., Nelson, M. (2008). Use of ezetimibe during HIV infection. J Antimicrob Chemother 0: dkn440v1-2 [Full Text]  
• Taylor, A. J., Nissen, S. E. (2008). Preliminary Observations From Preliminary Trial Results: Have We Finally Had Enough?. Circ Cardiovasc Qual Outcomes 1: 54-57 [Full Text]  
• Steinberg, D., Eichhorn, E. J., Connor, W. E., Diamond, G. A., Kaul, S., Blake, J. A., Davis, H. R. Jr., Murgolo, N. J., Graziano, M. P., Kaye, T., Akdim, F., de Groot, E., Kastelein, J. J.P., Brown, B. G. (2008). Simvastatin with or without ezetimibe in familial hypercholesterolemia.. NEJM 359: 529-530 [Full Text]  
• DAVIDSON, M. H. (2008). Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleveland Clinic Journal of Medicine 75: 479-496 [Full Text]